Loading
Led PROMIS, the trial that showed MRI can safely spare a quarter of men from prostate biopsy.
Hashim Ahmed (Imperial College London) was chief investigator of PROMIS, which showed multiparametric MRI has far higher sensitivity for clinically significant prostate cancer than TRUS biopsy and could allow 27% of men to avoid biopsy altogether. He leads focal therapy trials of HIFU and cryotherapy and the PART and CHRONOS studies comparing focal and radical treatment.
| Title | Journal | Year |
|---|---|---|
| Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS) | Lancet | 2017 |
| Focal therapy for localised prostate cancer: a phase I/II trial | Lancet Oncology | 2012 |
Shares Rakesh Heer, Caroline Moore, PRECISION, PROMIS and the tags prostate, imaging, focal-therapy.
Shares Prostate cancer and the tags prostate, imaging.
Shares TRANSFORM, Prostate cancer and the tag prostate.
Shares TRANSFORM, Prostate cancer and the tag prostate.
Shares Focused ultrasound & histotripsy, MRI, Prostate cancer.
Shares Prostate cancer and the tag prostate.
Shares Prostate cancer and the tag prostate.
Shares Prostate cancer and the tag prostate.